|
|
Overall mortality |
Mortality from endometrial cancer |
|
N |
Deaths N |
5-year survival
(95% CI) |
Unadjusted
HR (95% CI) |
P-value |
Adjusted HR
(95% CI)a |
P-value |
Deaths N |
5-year survival
(95% CI) |
Unadjusted
HR (95% CI) |
P-value |
Adjusted HR
(95% CI) b |
P-value |
All patients |
None |
87 |
11 |
87% (80-94) |
1c |
|
1c |
|
5 |
94% (89-99) |
1c |
|
1c |
|
Brachytherapy |
94 |
8 |
91% (86-97) |
0.7 (0.3-1.7) |
.388 |
1.1 (0.4-2.8) |
.892 |
5 |
94% (90-99) |
0.9 (0.3-3.2) |
.899 |
1.3 (0.4-4.8) |
.667 |
External +/- Brachytherapy |
89 |
14 |
84% (76-92) |
1.3 (0.6-2.9) |
.480 |
3.2 (1.2-8.7) |
.020 |
9 |
89% (82-96) |
1.9 (0.6-5.6) |
.260 |
3.6 (1.0-13.4) |
.059 |
Low risk (myometrial invasion <50%, grade 1-2) |
None |
61 |
6 |
90% (82-97) |
1c |
|
1c |
|
2 |
97% (92-100) |
1c |
|
1c |
|
Brachytherapy |
75 |
5 |
93% (88-99) |
0.7 (0.2-2.2) |
.426 |
1.6 (0.4-1.3)) |
.476 |
2 |
97% (93-100) |
0.8 (0.1-5.7) |
.832 |
1.7 (0.2-13.9) |
.642 |
External +/- Brachytherapy |
26 |
4 |
84% (70-99) |
1.7 (0.5-5.9) |
.639 |
6.4 (1.3-30.2) |
.020 |
3 |
89% (76-100) |
3.7 (0.6-22.4) |
.149 |
9.4 (1.0-86.7) |
.047 |
High risk (myometrial invasion <50%, grade 3 or myometrial invasion >=50%, grade 1-2) |
None |
26 |
5 |
80% (65-96) |
1c |
|
1c |
|
3 |
87% (74-100) |
1c |
|
1c |
|
Brachytherapy |
19 |
3 |
84% (68-100) |
0.8 (0.2-3.5) |
.802 |
1.0 (0.2-4.3) |
.973 |
3 |
84% (68-100) |
1.4 (0.3-6.9) |
.682 |
1.6 (0.3-8.1) |
.564 |
External +/- Brachytherapy |
63 |
10 |
90% (74-93) |
0.9 (0.3-2.5) |
.792 |
1.7 (0.5-6.3) |
.396 |
6 |
90% (82-98) |
0.9 (0.2-3.5) |
.838 |
1.9 (0.4-9.1) |
.453 |
aAdjusted for age (continuous), tumour risk category and sector of care
bAdjusted for age (continuous) and tumour risk category
cReference category |